Tenofovir disoproxil
- Generic Name
- Tenofovir disoproxil
- Brand Names
- Atripla, Cimduo, Complera, Delstrigo, Stribild, Symfi, Truvada, Viread, Tenofovir disoproxil Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C19H30N5O10P
- CAS Number
- 201341-05-1
- Unique Ingredient Identifier
- F4YU4LON7I
- Background
Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs). This drug is prescribed in combination with other drugs for the management of HIV infection as well as for Hepatitis B therapy. Tenofovir disoproxil was initially approved in 2001 .
- Indication
Tenofovir disoproxil is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients ≥2 years old and weighing ≥10 kg. It is also indicated for the treatment of chronic hepatitis B in patients ≥2 years old and weighing ≥10 kg.
Tenofovir disoproxil is also an ingredient in several combination products, all of which are indicated either alone or in combination with other antiretrovirals for the treatment of HIV-1 infection.
In addition, tenofovir disoproxil is available in combination with emtricitabine (under the brand name Truvada) for use as pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents weighing ≥ 35kg to reduce the risk of sexually-acquired HIV-1 infection.
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV
- Conditions
- HIV InfectionsHepatitis B
- First Posted Date
- 2002-04-09
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 90
- Registration Number
- NCT00033163
- Locations
- 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
🇺🇸Univ. of Cincinnati CRS, Cincinnati, Ohio, United States
Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People
- Conditions
- HIV Infections
- First Posted Date
- 2001-12-28
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 56
- Registration Number
- NCT00028366
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States
🇺🇸Case CRS, Cleveland, Ohio, United States
Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV
- Conditions
- HIV Infections
- First Posted Date
- 2001-12-05
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 53
- Registration Number
- NCT00027339
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States
🇺🇸Beth Israel Med. Ctr., ACTU, New York, New York, United States
The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT00007436
- Locations
- 🇺🇸
Northstar Med Clinic, Chicago, Illinois, United States
🇺🇸Anderson Clinical Research, Pittsburgh, Pennsylvania, United States
🇺🇸Physicans Home Service, Washington, District of Columbia, United States
Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 600
- Registration Number
- NCT00002450
- Locations
- 🇺🇸
Tower Infectious Diseases / Med Associates Inc, Los Angeles, California, United States
🇺🇸Remington Davis Inc, Columbus, Ohio, United States
🇺🇸Thomas Street Clinic, Houston, Texas, United States
Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 175
- Registration Number
- NCT00002415
- Locations
- 🇺🇸
Harbor UCLA Med Ctr, Torrance, California, United States
🇺🇸Hershey Med Ctr, Hershey, Pennsylvania, United States
🇺🇸San Francisco Veterans Adm Med Cntr, San Francisco, California, United States
Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT00016588
- Locations
- 🇺🇸
Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ, New York, New York, United States
A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 300
- Registration Number
- NCT00002453
- Locations
- 🇺🇸
Tenofovir Coordinating Center, Foster City, California, United States
Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT00011089
- Locations
- 🇺🇸
Medical Information, Foster City, California, United States
The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT00002396
- Locations
- 🇺🇸
San Francisco Gen Hosp, San Francisco, California, United States
🇺🇸Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Univ of Washington / AIDS Clinical Trial Unit, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.